AcadeMab Biomedical

Executive Summary

AcadeMab Biomedical Inc. is a Taiwan-based biotech company founded in 2020 that focuses on developing therapeutic antibodies and mRNA-LNP vaccines for oncology and infectious diseases. The company leverages a dual-engine platform combining advanced antibody discovery (phage display, human single B-cell, human antibody mouse) with proprietary ionizable lipid-based mRNA delivery to create next-generation biologics and vaccines. Its pipeline targets unmet needs such as EpCAM-positive solid tumors, HER3-driven resistance, dengue fever, and COVID-19. As a private company currently in Phase 1 clinical stage, AcadeMab is actively advancing its lead programs toward proof-of-concept data. The company's platform technology and focus on high-need areas position it as a potential player in the biotech landscape, though it remains early-stage with limited public financial disclosures. Its innovative approach and dual-platform strategy could attract partnership interest as pipeline milestones approach.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 trial for anti-EpCAM antibody in solid tumors40% success
• Q1 2026IND filing for HER3-targeted antibody program35% success
• Q2 2026Preclinical data release for dengue mRNA-LNP vaccine50% success